Clinical Cancer Research

We define a urinary three-metabolite signature that enables non-invasive identification of high-risk ovarian cancer patients beyond established clinical factors and may support molecular stratification and risk-adapted clinical decisions, thereby supporting the clinical scalability of urine as a matrix for metabolic risk profiling in ovarian cancer.

Efficacy was limited in what is the largest BTC cohort treated to date with combined anti-CTLA-4/PD-1 blockade. Encouraging activity was observed in the GBC subgroup. Further evaluation of checkpoint inhibition in BTC should focus on GBC patients.

The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with PARPi. With a 68% 6-month progression-free survival (PFS) rate, this combination may synergistically be able to overcome acquired PARPi resistance, particular…

Abstract Purpose: Ablative radiotherapy (RT) improves clinical outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Applicability to “supermassive” ICC remains uncertain given smaller tumor diameters in previous studies. We hypothesize that supermassive ICCs are not mutationally or histopathologically different from nonsupermassive ICCs and so would respond favorably to a…

Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.

LM-101 was well tolerated. The preliminary efficacy signal supports further evaluation of LM-101 plus rituximab in relapsed/refractory lymphoma.

These clinical and preclinical findings provide rationale for therapies to increase therapeutic index of aPD-1 therapy by diminishing presence of T cell-suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.

The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.

Desmoid tumours are a locally invasive neoplasm that can exhibit unpredictable clinical behaviour. While treatment options are numerous, few are supported by level 1 evidence. A recent phase 3 trial evaluated the efficacy of long-used pegylated liposomal doxorubicin in patients with progressive desmoid tumours.

The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.

Cabazitaxel and carboplatin followed by abiraterone, together with ADT, was feasible, safe, and efficacious in patients with high-volume mCSPC, and warrants further study in larger randomized trials.

NT-I7 has the potential to maintain and increase lymphocyte counts in HGG patients and warrants further investigation, particularly in combination with immune-based therapies.

EZFB significantly improved survival outcomes compared with regorafenib in patients with mCRC as a third-line treatment, with a manageable safety profile. Further investigation is warranted, given the clinically meaningful improvements in progression-free survival and overall survival.

Our study highlights key molecular and immune differences across R/M SCCHN subgroups, identifies potential biomarkers, and suggests biological rationales for tailored therapeutic strategies.

Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.

CN amplifications are prevalent and diverse biomarkers and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification f…

The CA19-9/FUT2/3 panel was the best performing panel in this biomarker bakeoff. Its evaluation in larger studies is warranted. Biomarker bakeoffs are an effective strategy for comparing the performance of promising biomarkers for pancreatic cancer early detection, and the PCDC is well poised to conduct such studies. Recommendations for performing such studies are provided.

These findings suggest that ctDNA may be a modality to identify older patients who can safely receive long-term pET, warranting future evaluation in a randomized setting.

Eribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma through two prospective international trials. While encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultra-rare …

In 390 patients with stage I-III hormone-receptor positive/HER2-negative breast tumors higher number of Tumor Infiltrating Lymphocytes (TILs)-subtypes, regardless of whether they were immunostimulatory or immunosuppressive, including T-regulatory cells and CD8- and non-CD8 T-cells, are associated with improved distant disease free survival and overall survival at 8 years follow-up.